Fig. 2

GLPG1790 decreases ERMS cell viability by inducing concomitant cell death and morphology changes in growth arrested cells. a Dose-dependent effect of GLPG1790 on viability of RD and TE671 cells after 48 h of treatment. Cell viability was measured by trypan blue dye exclusion test. Results represent the mean values of four independent experiments ±SD. b Cell lysates from ERMS cells untreated (DMSO) (−) or treated (+) with 3.5 μM GLPG1790 for the indicated times were analysed by immunoblotting with specific antibodies for indicated proteins. Representative of four independent experiments. c RD and TE671 cells, grown in adherent conditions, were treated with 3.5 μM GLPG1790 for the indicated times. Percentage of proliferating (upper panel) or dead (lower panel) cells were obtained by trypan blue dye exclusion test. Results represent the mean values ± SD of four independent experiments. d RD and TE671, cells grown in non-adherent conditions, were treated with 3.5 μM GLPG1790 for the indicated times. Percentage of proliferating (upper panel) or dead (lower panel) cells were obtained by trypan blue dye exclusion test. Results represents the mean value of four independent experiments ±SD. e Cellular morphology of ERMS cells untreated (DMSO) or treated with 3.5 μM GLPG1790 for 72 h was analysed under light microscope at ×20 magnification. In GLPG1790 treated cells, more elongated cellular bodies were evident, many of which formed multinucleated myotube-like structures. Representative of three independent experiments